Midi Health presents sermorelin within a wider service focused on midlife health. Its product page starts at $179 per month, while its pricing page lists separate visit charges. That distinction matters if you are comparing a medication price with another service that bundles some clinical care.
We checked Midi’s public product, safety, and pricing pages on September 21, 2026, including the expanded insurance FAQ. We did not enroll, order medication, or test the service. CoreAge Rx receives commercial placement on this site; Midi’s published information is assessed with the same limits around pricing, quality, and clinical claims.
Midi offers a broader midlife-care setting, with separate medication and visit costs. Confirm your full quote and the clinical reason for adding sermorelin.
Separate the medication price from the visit
The $179 product figure is a starting monthly medication price. Midi's general pricing page lists a $250 self-pay first visit and a $150 returning visit. These are not three interchangeable prices for the same thing, and the number of follow-up appointments needed has not been established for an individual reader.
Ask for the expected first appointment, medication, testing, and follow-up charges in one written estimate. If a promotion changes the quote, record its duration and later price. Our sermorelin cost guide explains how to compare the same care period without assuming the smallest visible number covers every service.
Insurance participation does not settle medication coverage
Midi's expanded pricing FAQ says prescriptions, laboratory tests, and imaging are billed separately from visits. It notes that insurance may cover some or all of those expenses depending on the plan. A covered consultation therefore does not establish coverage for compounded sermorelin.
Check the specific clinician, service, pharmacy benefit, and expected patient responsibility with the insurer. Ask how the service handles a denied claim or an out-of-network charge before booking. The insurance, HSA, and FSA guide helps separate coverage from the different question of whether an expense can be paid through a tax-advantaged account.
The published product is an injection
Midi's product page describes subcutaneous administration, and its safety sheet names sermorelin acetate with other formulation ingredients. That is useful product information, but it is not a patient-specific prescription or a guarantee that every later supply has identical instructions.
Ask for the dispensing pharmacy and the formulation on the proposed order. Review the actual label when it arrives, including storage and the beyond-use date. Our acetate-name guide explains the name, and the expiration guide explains why a monthly purchase does not override the date assigned to a particular preparation.
Read the hormone language carefully
The page markets sermorelin as non-hormonal while explaining that it stimulates the growth-hormone pathway. For a reader considering menopause care, that wording should not be understood as meaning the medicine has no endocrine effects or cannot interact with an existing treatment plan.
Sermorelin is not the same medicine as estrogen, progesterone, testosterone, or injected growth hormone. That distinction alone does not establish that it is safer or more effective for your goals. The menopause guide discusses why symptoms need an appropriate assessment, and why using a different biological pathway does not automatically justify adding another prescription.
Midlife symptoms deserve a specific clinical explanation
Midi highlights energy, sleep, metabolism, and mental clarity. These are understandable reasons to seek help, but they do not identify one diagnosis. A provider should explain why a particular symptom suggests this treatment and which alternatives or contributing conditions have been considered.
The page's expected-results language is marketing information, not a measured outcome for the reader. If low energy or brain fog is the main concern, use our fatigue guide and memory guide to prepare questions. Ask what improvement would be meaningful, when it would be reassessed, and what would lead the clinician to change course.
Coordinate with existing care rather than relying on a short FAQ
Midi says sermorelin may be used alongside hormone replacement therapy and describes precautions in its safety material. Those statements do not establish that the combination is appropriate for everyone. The clinician needs the actual medicine list, health history, and relevant records.
Ask how Midi will coordinate with the clinician managing an existing hormone, thyroid, cancer-related, or other health concern. A general internet eligibility list should not be used to diagnose yourself or to omit a condition from intake. The drug-interaction guide helps organize the discussion without turning provider marketing into individualized medical clearance.
Clarify the follow-up pathway and pharmacy responsibility
Midi describes virtual assessment, pharmacy delivery, and subsequent adjustments to the care plan. That tells you how the service is intended to work. It does not independently establish appointment availability, shipping speed, or how quickly a particular symptom will reach the prescriber.
Ask how to contact the clinical team between visits and the pharmacy about a label or storage problem. Confirm any cost for an extra appointment. Compounded sermorelin is not an FDA-approved finished product, even when a clinician prescribes it. The pharmacy checklist helps make the roles of prescriber, service, and dispenser clear before treatment starts.
Our assessment of Midi’s published offer
Midi may be worth investigating for someone already seeking broader midlife care, but that setting should not make a sermorelin prescription automatic. Its clearest purchasing distinction is the separation between medication and clinical-service costs. The unresolved items are the patient-specific total, pharmacy, monitoring plan, and reason for treatment.
Read the CoreAge Rx versus Midi comparison to organize two complete quotes. For another service focused on women, see the Embody Her Health review. Neither article establishes a clinical winner. A clear explanation of whether another medicine is needed matters more than an appealing starting rate or a general promise of renewed vitality.
Sources behind this article
Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.
- Midi Health: SermorelinProvider primary source · Checked September 21, 2026. Starting medication price and provider claims; no enrollment or clinical testing.
- Midi Health: Insurance and pricingProvider primary source · Self-pay visit rates are separate from medication pricing. Insurance and additional costs depend on the plan.
- Midi Health: Sermorelin safety sheetProvider primary source · Provider formulation and safety information, not FDA approval or a personalized prescription.
- USP: Compounded preparation monographsStandards organization · Canonical page blocked automated retrieval; indexed USP-hosted overview confirms the general BUD definition. No numerical or sermorelin-specific BUD rule is asserted.
- FDA: Managing the benefits and risks of medicinesUS regulator · General questions for evaluating benefit, follow-up and new medicines.
- FDA: Compounding questions and answersUS regulator · Compounded medicines differ from FDA-approved generic drugs.
- CoreAge Rx: Sermorelin product pageProvider primary source · Live product page; starting price is not a verified checkout total.